Karyopharm Therapeutics - KPTI Stock Forecast, Price & News

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on KPTI shares. HC Wainwright lowered their price objective on shares of Karyopharm Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Friday. Barclays reduced their target price on shares of Karyopharm Therapeutics from $14.00 to $8.00 and set an "overweight" rating on the stock in a report on Friday. Canaccord Genuity Group reduced their target price on shares of Karyopharm Therapeutics from $20.00 to $10.00 in a report on Monday, April 11th. Finally, Robert W. Baird reduced their target price on shares of Karyopharm Therapeutics from $17.00 to $14.00 and set an "outperform" rating on the stock in a report on Friday. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $10.25.

Karyopharm Therapeutics Stock Up 10.3 %

Shares of KPTI Stock traded up $0.48 during trading hours on Monday, hitting $5.16. 2,544,801 shares of the company were exchanged, compared to its average volume of 2,956,139. The firm has a market cap of $409.80 million, a PE ratio of -3.72 and a beta of 0.02. Karyopharm Therapeutics has a 1 year low of $4.00 and a 1 year high of $14.73. The firm has a fifty day moving average of $4.98 and a 200 day moving average of $6.74.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.10. The company had revenue of $47.67 million for the quarter, compared to analysts' expectations of $34.78 million. During the same quarter in the previous year, the company earned ($0.77) earnings per share. Analysts expect that Karyopharm Therapeutics will post -2.06 earnings per share for the current year.

Insider Transactions at Karyopharm Therapeutics

In other news, Director Deepika Pakianathan sold 325,977 shares of the stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $6.50, for a total transaction of $2,118,850.50. Following the transaction, the director now directly owns 18,731 shares in the company, valued at approximately $121,751.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 336,407 shares of company stock worth $2,174,368 in the last three months. Company insiders own 10.24% of the company's stock.